Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

The discovery of robust antidepressant actions exerted by the N-methyl-D-aspartate receptor
(NMDAR) antagonist (R, S)-ketamine has been a crucial breakthrough in mood disorder …

Ketamine is a well-characterized NMDA receptor (NMDAR) antagonist, although the
relevance of this pharmacology to its rapid (within hours of administration) antidepressant …

Introduction Ketamine can produce rapid-acting antidepressant effects. Esketamine
(Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment …

Cognitive impairment has been observed in patients with various psychiatric disorders,
including schizophrenia, major depressive disorder (MDD), and bipolar disorder (BD) …

Impaired cognition is often overlooked in the clinical management of depression, despite its
association with poor psychosocial functioning and reduced clinical engagement. There is …

In the mammalian brain, glutamate is regarded to be the primary excitatory neurotransmitter
due to its widespread distribution and wide range of metabolic functions. Glutamate plays …

Purpose This study aims to evaluate the effects of the intraoperative application of low-dose
esketamine on postoperative neurocognitive dysfunction (PND) in elderly patients …

Anorexia nervosa (AN) is a highly complex disorder to treat, especially in severe and
enduring cases. Whilst the precise aetiology of the disorder is uncertain, malnutrition and …

Over the past two decades, ketamine has emerged as a novel effective and rapid-acting
antidepressant. While the vast majority of studies on ketamine have focused on its ability to …